Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | HGEN | Stock Option (Right to Buy) | Disposed to Issuer | -$80K | -17.7K | -100% | $4.53 | 0 | Nov 23, 2021 | Common Stock | 17.7K | $5.93 | Direct | F1 |
Id | Content |
---|---|
F1 | As reported in a Form 8-K filed by Humanigen, Inc. (the "Company") on November 26, 2021, with the approval of the compensation committee of the board of directors of the Company, the reporting person accepted the Company's offer to rescind his participation in the program pursuant to which the reporting person had agreed to receive stock options in lieu of 50% of his base salary for the fourth quarter of 2021, or $79,959. As a result, the stock option granted to the reporting person on September 30, 2021 was cancelled, and the reporting person will receive 100% of his base salary for the fourth quarter of 2021 in cash. The amount shown in column 8 equals the fair value of the option on the grant date of September 30, 2021 as calculated using the Black-Scholes options pricing model. |